PT2529020T - Plataforma de fabrico escalável para purificação de vetor viral e vetores virais assim purificados para utilização na terapia génica - Google Patents

Plataforma de fabrico escalável para purificação de vetor viral e vetores virais assim purificados para utilização na terapia génica

Info

Publication number
PT2529020T
PT2529020T PT117375089T PT11737508T PT2529020T PT 2529020 T PT2529020 T PT 2529020T PT 117375089 T PT117375089 T PT 117375089T PT 11737508 T PT11737508 T PT 11737508T PT 2529020 T PT2529020 T PT 2529020T
Authority
PT
Portugal
Prior art keywords
purified
gene therapy
viral
manufacturing platform
scalable manufacturing
Prior art date
Application number
PT117375089T
Other languages
English (en)
Portuguese (pt)
Inventor
Fraser Wright John
Qu Guang
Hauck Bernd
High Katherine
Original Assignee
Childrens Hospital Philadelphia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Hospital Philadelphia filed Critical Childrens Hospital Philadelphia
Publication of PT2529020T publication Critical patent/PT2529020T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/23—Parvoviridae, e.g. feline panleukopenia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/864—Parvoviral vectors, e.g. parvovirus, densovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/864—Parvoviral vectors, e.g. parvovirus, densovirus
    • C12N15/8645—Adeno-associated virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01064—Retinoid isomerohydrolase (3.1.1.64)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Manufacturing & Machinery (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT117375089T 2010-01-28 2011-01-25 Plataforma de fabrico escalável para purificação de vetor viral e vetores virais assim purificados para utilização na terapia génica PT2529020T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29918410P 2010-01-28 2010-01-28

Publications (1)

Publication Number Publication Date
PT2529020T true PT2529020T (pt) 2018-07-30

Family

ID=44319714

Family Applications (1)

Application Number Title Priority Date Filing Date
PT117375089T PT2529020T (pt) 2010-01-28 2011-01-25 Plataforma de fabrico escalável para purificação de vetor viral e vetores virais assim purificados para utilização na terapia génica

Country Status (13)

Country Link
US (4) US9408904B2 (enExample)
EP (1) EP2529020B1 (enExample)
JP (4) JP2013517798A (enExample)
CN (2) CN102947453A (enExample)
AU (1) AU2011209743B2 (enExample)
CA (1) CA2787827C (enExample)
DK (1) DK2529020T3 (enExample)
ES (1) ES2680915T3 (enExample)
IL (1) IL221158B (enExample)
IN (1) IN2012DN06629A (enExample)
MX (1) MX340102B (enExample)
PT (1) PT2529020T (enExample)
WO (1) WO2011094198A1 (enExample)

Families Citing this family (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9217155B2 (en) 2008-05-28 2015-12-22 University Of Massachusetts Isolation of novel AAV'S and uses thereof
WO2010138263A2 (en) 2009-05-28 2010-12-02 University Of Massachusetts Novel aav 's and uses thereof
MX340102B (es) * 2010-01-28 2016-06-24 The Children's Hospital Of Philadelphia * Una plataforma de fabricacion ajustable en escala, para la purificacion de vector viral y vectores virales asi purificados para el uso en terapia de genes.
WO2011133874A1 (en) 2010-04-23 2011-10-27 University Of Massachusetts Multicistronic expression constructs
US9102949B2 (en) 2010-04-23 2015-08-11 University Of Massachusetts CNS targeting AAV vectors and methods of use thereof
WO2013036118A1 (en) * 2011-09-08 2013-03-14 Uniqure Ip B.V. Removal of contaminating viruses from aav preparations
ES2949648T3 (es) 2012-12-20 2023-10-02 Purdue Research Foundation Células T que expresan un receptor antigénico quimérico como terapia contra el cáncer
FR3002237B1 (fr) * 2013-02-15 2017-12-15 Genethon Methodes pour la production de particules virales aav double brin
CA2930872C (en) 2013-11-26 2022-05-31 University Of Florida Research Foundation, Incorporated Adeno-associated virus vectors for treatment of glycogen storage disease
GB201401707D0 (en) 2014-01-31 2014-03-19 Sec Dep For Health The Adeno-associated viral vectors
WO2015127128A2 (en) 2014-02-19 2015-08-27 University Of Massachusetts Recombinant aavs having useful transcytosis properties
AU2015231294B2 (en) 2014-03-18 2020-10-29 University Of Massachusetts rAAV-based compositions and methods for treating amyotrophic lateral sclerosis
SI3119437T1 (sl) * 2014-03-21 2020-01-31 Genzyme Corporation Genska terapija za retinitis pigmentoza
JP6741590B2 (ja) 2014-04-25 2020-08-19 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア コレステロールレベルを低下させるためのｌｄｌｒ変異体および組成物中でのそれらの使用
US10975391B2 (en) 2014-04-25 2021-04-13 University Of Massachusetts Recombinant AAV vectors useful for reducing immunity against transgene products
US10689653B2 (en) 2014-06-03 2020-06-23 University Of Massachusetts Compositions and methods for modulating dysferlin expression
WO2016054557A1 (en) 2014-10-03 2016-04-07 University Of Massachusetts Novel high efficiency library-identified aav vectors
WO2016054554A1 (en) 2014-10-03 2016-04-07 University Of Massachusetts Heterologous targeting peptide grafted aavs
CA2964272A1 (en) 2014-10-21 2016-04-28 Guangping Gao Recombinant aav variants and uses thereof
WO2016083560A1 (en) * 2014-11-28 2016-06-02 Uniqure Ip B.V. Dna impurities in a composition comprising a parvoviral virion
US10415044B2 (en) 2014-12-23 2019-09-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adeno-associated virus vectors encoding modified G6PC and uses thereof
EP3245218A4 (en) 2015-01-13 2018-10-03 Alfa Wassermann, Inc. Methods of purifying adeno-associated virus (aav) and/or recombinant adeno-associated virus (raav) and gradients and flow-through buffers therefore
EP3054006A1 (en) 2015-02-09 2016-08-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Recombinant adeno-associated virus particle purification with multiple-step anion exchange chromatography
EP3054007A1 (en) 2015-02-09 2016-08-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Recombinant adeno-associated virus particle purification comprising an immuno-affinity purification step
US10584321B2 (en) 2015-02-13 2020-03-10 University Of Massachusetts Compositions and methods for transient delivery of nucleases
EP3262162A4 (en) * 2015-02-23 2018-08-08 Voyager Therapeutics, Inc. Regulatable expression using adeno-associated virus (aav)
CN108093639B (zh) 2015-04-16 2022-07-19 埃默里大学 用于肝脏中蛋白质表达的重组启动子和载体及其用途
ES2856936T3 (es) 2015-04-23 2021-09-28 Univ Washington State Suministro del gen Smad7 como un agente terapéutico
CA3021949C (en) 2015-04-24 2023-10-17 University Of Massachusetts Modified aav constructs and uses thereof
DK3364997T5 (da) 2015-10-22 2024-09-30 Univ Massachusetts Aspartoacylase genterapi til behandling af canavans sygdom
CA3002980A1 (en) 2015-10-22 2017-04-27 University Of Massachusetts Prostate-targeting adeno-associated virus serotype vectors
CN105420275A (zh) * 2015-11-27 2016-03-23 中国科学院苏州生物医学工程技术研究所 制备外源功能基因定点整合的人神经干细胞的方法
ES2918998T3 (es) 2015-12-11 2022-07-21 Univ Pennsylvania Método de purificación escalable para AAVrh10
MX2018007080A (es) * 2015-12-11 2018-11-12 Univ Pennsylvania Terapia genica para tratar hipercolesterolemia familiar.
EP3387117B1 (en) * 2015-12-11 2022-11-23 The Trustees Of The University Of Pennsylvania Scalable purification method for aav8
WO2017100674A1 (en) * 2015-12-11 2017-06-15 The Trustees Of The University Of Pennsylvania Scalable purification method for aav1
US11098286B2 (en) 2015-12-11 2021-08-24 The Trustees Of The University Of Pennsylvania Scalable purification method for AAV9
WO2017106537A2 (en) 2015-12-18 2017-06-22 Sangamo Biosciences, Inc. Targeted disruption of the mhc cell receptor
WO2017106528A2 (en) 2015-12-18 2017-06-22 Sangamo Biosciences, Inc. Targeted disruption of the t cell receptor
CA3011939A1 (en) 2016-02-02 2017-08-10 University Of Massachusetts Method to enhance the efficiency of systemic aav gene delivery to the central nervous system
EP3769775A3 (en) 2016-02-02 2021-03-17 Sangamo Therapeutics, Inc. Compositions for linking dna-binding domains and cleavage domains
FI3411484T3 (fi) 2016-02-05 2023-11-15 Univ Emory Yksisäikeisen tai itsekomplementaarisen adenoassosioidun viruksen 9 injektio serebrospinaaliseen fluidiin
WO2017139643A1 (en) 2016-02-12 2017-08-17 University Of Massachusetts Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization
HUE056854T2 (hu) 2016-03-31 2022-03-28 Spark Therapeutics Inc Oszlop alapú, teljes mértékben méretezhetõ rAAV elõállítási eljárás
US11207426B2 (en) 2016-04-05 2021-12-28 University Of Massachusetts Compositions and methods for selective inhibition of grainyhead-like protein expression
JP7282521B2 (ja) 2016-04-08 2023-05-29 パーデュー・リサーチ・ファウンデイション Ｃａｒ ｔ細胞療法のための方法および組成物
US11413356B2 (en) 2016-04-15 2022-08-16 University Of Massachusetts Methods and compositions for treating metabolic imbalance
US11882815B2 (en) 2016-06-15 2024-01-30 University Of Massachusetts Recombinant adeno-associated viruses for delivering gene editing molecules to embryonic cells
GB201612248D0 (en) 2016-07-14 2016-08-31 Puridify Ltd New process
US20190284576A1 (en) * 2016-07-21 2019-09-19 Spark Therapeutics, Inc. SCALABLE HIGH RECOVERY METHODS FOR PRODUCING HIGH YIELD RECOMBINANT ADENO-ASSOCIATED VIRAL (rAAV) VECTOR AND RECOMBINANT ADENO-ASSOCIATED VIRAL (rAAV) VECTORS PRODUCED THEREBY
US11883470B2 (en) 2016-07-25 2024-01-30 The Trustees Of The University Of Pennsylvania Compositions comprising a lecithin cholesterol acyltransferase variant and uses thereof
CA3034527A1 (en) 2016-08-23 2018-03-01 Emmanuel John Simons Compositions and methods for treating non-age-associated hearing impairment in a human subject
WO2018039448A1 (en) 2016-08-24 2018-03-01 Sangamo Therapeutics, Inc. Engineered target specific nucleases
HRP20212025T1 (hr) 2016-08-24 2022-04-01 Sangamo Therapeutics, Inc. Regulacija ekspresije gena pomoću projektiranih nukleaza
US10457940B2 (en) 2016-09-22 2019-10-29 University Of Massachusetts AAV treatment of Huntington's disease
WO2018071831A1 (en) 2016-10-13 2018-04-19 University Of Massachusetts Aav capsid designs
MX2019004784A (es) * 2016-11-04 2019-08-12 Baxalta Inc Metodos de purificacion del virus adeno-asociado.
EP3321357A1 (en) 2016-11-09 2018-05-16 Deutsches Krebsforschungszentrum Scalable process for oncolytic rat parvovirus h-1 production and purification based on isoelectric point-based elimination of empty particles
US20190367944A1 (en) 2017-01-30 2019-12-05 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Recombinant virus vectors for the treatment of glycogen storage disease
CN110612119B (zh) 2017-02-07 2024-10-29 西雅图儿童医院（Dba西雅图儿童研究所） 磷脂醚(ple)car t细胞肿瘤靶向(ctct)剂
JP2020510648A (ja) 2017-02-20 2020-04-09 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 家族性高コレステロール血症を処置するための遺伝子治療
US11850262B2 (en) 2017-02-28 2023-12-26 Purdue Research Foundation Compositions and methods for CAR T cell therapy
CA3059213A1 (en) 2017-05-09 2018-11-15 University Of Massachusetts Methods of treating amyotrophic lateral sclerosis (als)
WO2018208973A1 (en) 2017-05-09 2018-11-15 Emory University Clotting factor variants and their use
BR112019025792A2 (pt) 2017-06-07 2020-07-07 Spark Therapeutics, Inc. agentes de aperfeiçoamento para transfecção de células melhoradas e/ou produção de vetor raav
SG11201913157RA (en) * 2017-06-30 2020-01-30 Spark Therapeutics Inc Aav vector column purification methods
WO2019060686A1 (en) 2017-09-22 2019-03-28 University Of Massachusetts NEW DUAL EXPRESSION VECTORS OF SOD1 AND USES THEREOF
KR20240164969A (ko) 2017-10-20 2024-11-21 더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 Nt-3 유전자 치료를 위한 방법 및 물질
EP3707264A1 (en) * 2017-11-08 2020-09-16 Avexis Inc. Means and method for preparing viral vectors and uses of same
BR112020014913A2 (pt) 2018-01-22 2020-12-08 Seattle Children's Hospital (dba Seattle Children's Research Institute) Métodos para uso de células t car
PE20212076A1 (es) 2018-02-01 2021-10-26 Homology Medicines Inc Composiciones de virus adeno-asociado para restaurar la funcion del gen pah y metodos de uso de las mismas
US10610606B2 (en) 2018-02-01 2020-04-07 Homology Medicines, Inc. Adeno-associated virus compositions for PAH gene transfer and methods of use thereof
SG11202007426XA (en) 2018-02-06 2020-09-29 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors
US11306329B2 (en) 2018-02-19 2022-04-19 City Of Hope Adeno-associated virus compositions for restoring F8 gene function and methods of use thereof
CA3091674A1 (en) 2018-02-23 2019-08-29 Endocyte, Inc. Sequencing method for car t cell therapy
CA3091810A1 (en) 2018-03-02 2019-09-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of il-34 to treat retinal inflammation and neurodegeneration
BR112020020174A2 (pt) * 2018-04-05 2021-01-19 Nightstarx Limited Composições de aav, métodos de fabricação e métodos de uso
US12228571B2 (en) 2018-06-08 2025-02-18 Novartis Ag Cell-based assay for measuring drug product potency
US12163129B2 (en) 2018-06-08 2024-12-10 University Of Massachusetts Antisense oligonucleotides to restore dysferlin protein expression in dysferlinopathy patient cells
CA3103740A1 (en) 2018-06-29 2020-01-02 Wuhan Neurophth Biotechnology Limited Company Compositions and methods for treating leber's hereditary optic neuropathy
EP3840785A4 (en) 2018-08-20 2022-07-13 Wuhan Neurophth Biotechnology Limited Company COMPOSITIONS AND METHODS FOR THE TREATMENT OF LEBERIAN OPTIC ATROPHY
IL322436A (en) 2018-09-21 2025-09-01 Acuitas Therapeutics Inc Systems and methods for producing lipid nanoparticles and liposomes
TWI897418B (zh) * 2018-11-30 2025-09-11 瑞士商諾華公司 Aav病毒載體及其用途
ES2969222T3 (es) 2018-12-18 2024-05-17 Ultragenyx Pharmaceutical Inc Métodos y composiciones para el tratamiento de enfermedades del almacenamiento de glucógeno
TWI848038B (zh) 2019-01-04 2024-07-11 美商奧崔基尼克斯製藥公司 用於治療威爾森氏症之基因療法構築體
WO2020146805A1 (en) 2019-01-11 2020-07-16 Acuitas Therapeutics, Inc. Lipids for lipid nanoparticle delivery of active agents
AU2020208467A1 (en) * 2019-01-18 2021-08-05 Voyager Therapeutics, Inc. Methods and systems for producing AAV particles
WO2020264254A1 (en) 2019-06-28 2020-12-30 Crispr Therapeutics Ag Materials and methods for controlling gene editing
KR20220035937A (ko) 2019-07-25 2022-03-22 노파르티스 아게 조절 가능한 발현 시스템
WO2021062012A1 (en) 2019-09-25 2021-04-01 Emory University Use of klk10 and engineered derivatizations thereof
CN113025633B (zh) 2019-12-09 2024-08-27 武汉纽福斯生物科技有限公司 编码人nadh脱氢酶亚单位1蛋白的核酸及其应用
WO2021124152A1 (en) 2019-12-19 2021-06-24 Pfizer Inc. Compositions and methods for nucleic acid transfection using cationic polymers and stabilizers
TW202140791A (zh) 2020-01-13 2021-11-01 美商霍蒙拉奇醫藥公司 治療苯酮尿症之方法
CA3165922A1 (en) 2020-01-17 2021-07-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Gene therapy for treatment of crx-autosomal dominant retinopathies
CA3164714A1 (en) 2020-02-14 2021-08-19 Ultragenyx Pharmaceutical Inc. Gene therapy for treating cdkl5 deficiency disorder
BR112022016596A2 (pt) 2020-02-21 2022-11-16 Akouos Inc Composições e métodos para o tratamento de debilitação auditiva não associada à idade em um indivíduo humano
TW202208632A (zh) 2020-05-27 2022-03-01 美商同源醫藥公司 用於恢復ｐａｈ基因功能的腺相關病毒組成物及其使用方法
BR112023000327A2 (pt) 2020-07-16 2023-01-31 Acuitas Therapeutics Inc Lipídeos catiônicos para o uso em nanopartículas lipídicas
CN116261483A (zh) * 2020-08-18 2023-06-13 赛多利斯比亚分离有限责任公司 多模式金属亲和加工衣壳
US20230383278A1 (en) 2020-09-18 2023-11-30 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Novel adeno-associated viral (aav) vectors to treat hereditary methylmalonic acidemia (mma) caused by methylmalonyl-coa mutase (mmut) deficiency
EP4229204A1 (en) 2020-10-15 2023-08-23 F. Hoffmann-La Roche AG Nucleic acid constructs for simultaneous gene activation
JP2023546116A (ja) 2020-10-15 2023-11-01 エフ． ホフマン－ラ ロシュ アーゲー Ｖａ ｒｎａ転写のための核酸構築物
CN117980484A (zh) 2021-09-16 2024-05-03 诺华股份有限公司 新颖的转录因子
KR20240123832A (ko) 2021-12-16 2024-08-14 아퀴타스 테라퓨틱스 인크. 지질 나노입자 제형에 사용하기 위한 지질
WO2023196898A1 (en) 2022-04-07 2023-10-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Beta globin mimetic peptides and their use
CN118974274A (zh) 2022-04-13 2024-11-15 豪夫迈·罗氏有限公司 用于确定aav基因组的方法
JP2025517628A (ja) 2022-05-06 2025-06-10 ノバルティス アーゲー 新規の組換えａａｖ ｖｐ２融合ポリペプチド
JP2025517987A (ja) 2022-05-23 2025-06-12 エフ． ホフマン－ラ ロシュ アーゲー Ａａｖ粒子血清型およびａａｖ粒子負荷状態の識別のためのラマンベースの方法
AU2023278422A1 (en) 2022-06-03 2024-11-14 F. Hoffmann-La Roche Ag Method for producing recombinant aav particles
CA3261054A1 (en) 2022-07-14 2024-01-18 F. Hoffmann-La Roche Ag PROCESS FOR THE PRODUCTION OF RECOMBINANT ADENO-ASSOCIATED VIRUS PARTICLES
KR20250067819A (ko) 2022-09-12 2025-05-15 에프. 호프만-라 로슈 아게 핵산 포함 및 핵산 비포함 aav 입자를 분리하는 방법
EP4662490A1 (en) 2023-02-07 2025-12-17 F. Hoffmann-La Roche AG Method for the detection of anti-aav particle antibodies
WO2024168358A1 (en) 2023-02-10 2024-08-15 Expression Therapeutics, Llc Lentiviral system
WO2024178113A1 (en) 2023-02-22 2024-08-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant adeno-associated virus vectors lacking an immunodominant t cell epitope and use thereof
AU2024240009A1 (en) 2023-03-17 2025-09-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for treatment of age-related macular degeneration
CN120835797A (zh) 2023-03-21 2025-10-24 豪夫迈·罗氏有限公司 用于产生重组aav颗粒制备物的方法
WO2025090942A1 (en) * 2023-10-26 2025-05-01 University Of Notre Dame Du Lac Gene therapy for treatment of neurometabolic disease
WO2025168663A1 (en) 2024-02-09 2025-08-14 F. Hoffmann-La Roche Ag Method for producing recombinant adeno-associated viral particles
WO2025252480A1 (en) 2024-06-07 2025-12-11 F. Hoffmann-La Roche Ag Method for purifying plasmid dna

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001650A (en) 1995-08-03 1999-12-14 Avigen, Inc. High-efficiency wild-type-free AAV helper functions
US6004797A (en) 1995-11-09 1999-12-21 Avigen, Inc. Adenovirus helper-free recombinant AAV Virion production
JP4289687B2 (ja) * 1997-03-14 2009-07-01 ザ チルドレンズ ホスピタル オブ フィラデルフィア 血友病の治療のための遺伝子治療で使用する方法と組成物
US6989264B2 (en) * 1997-09-05 2006-01-24 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
DE69941905D1 (de) * 1998-11-10 2010-02-25 Univ North Carolina Virusvektoren und verfahren für ihre herstellung und verabreichung.
DK1190055T3 (da) * 1999-06-30 2008-09-22 Univ Tulane Human endogen retrovirus
AU2001249389A1 (en) * 2000-03-22 2001-10-03 The Children's Hospital Of Philadelphia Modified blood clotting factors and methods of use
US6593123B1 (en) 2000-08-07 2003-07-15 Avigen, Inc. Large-scale recombinant adeno-associated virus (rAAV) production and purification
AU2003253595A1 (en) * 2002-04-05 2003-11-03 The Children's Hospital Of Philadelphia Methods for the production of chimeric adeno-associated virus (aav) vectors, compositions of chimeric aav vectors, and methods of use thereof
DK2277996T3 (da) * 2003-05-21 2014-10-20 Genzyme Corp Fremgangsmåder til fremstilling af præparationer af rekombinante aav-virioner, der i hovedsagen er fri for tomme capsider
JP2008501339A (ja) * 2004-06-01 2008-01-24 ジェンザイム・コーポレイション Ａａｖベクターの凝集を防ぐための組成物およびその方法
CN1873012A (zh) * 2005-06-01 2006-12-06 上海二医新生基因科技有限公司 重组腺相关病毒（rAAV）载体大规模生产新工艺
CN101528916B (zh) * 2006-04-28 2013-09-04 宾夕法尼亚大学托管会 规模可调的aav生产方法
WO2008128251A1 (en) * 2007-04-17 2008-10-23 The Children's Hospital Of Philadelphia Humanized viral vectors and methods of use thereof
US9169491B2 (en) * 2008-06-18 2015-10-27 Oxford Biomedica (Uk) Limited Virus purification
MX340102B (es) * 2010-01-28 2016-06-24 The Children's Hospital Of Philadelphia * Una plataforma de fabricacion ajustable en escala, para la purificacion de vector viral y vectores virales asi purificados para el uso en terapia de genes.

Also Published As

Publication number Publication date
ES2680915T3 (es) 2018-09-11
IL221158B (en) 2018-07-31
US11878056B2 (en) 2024-01-23
EP2529020A1 (en) 2012-12-05
JP2013517798A (ja) 2013-05-20
EP2529020B1 (en) 2018-04-25
US20130072548A1 (en) 2013-03-21
CN105838737A (zh) 2016-08-10
MX2012008757A (es) 2012-11-06
AU2011209743A1 (en) 2012-08-23
JP6991095B2 (ja) 2022-01-12
US20190321463A1 (en) 2019-10-24
US9408904B2 (en) 2016-08-09
JP2018046820A (ja) 2018-03-29
US20160206706A1 (en) 2016-07-21
CA2787827C (en) 2020-11-10
WO2011094198A1 (en) 2011-08-04
US10328145B2 (en) 2019-06-25
CN102947453A (zh) 2013-02-27
AU2011209743B2 (en) 2016-03-10
JP2018121653A (ja) 2018-08-09
EP2529020A4 (en) 2013-10-16
IN2012DN06629A (enExample) 2015-10-23
US20200405845A1 (en) 2020-12-31
CA2787827A1 (en) 2011-08-04
DK2529020T3 (en) 2018-08-06
JP2016185153A (ja) 2016-10-27
MX340102B (es) 2016-06-24
BR112012018899A2 (pt) 2015-09-15

Similar Documents

Publication Publication Date Title
PT2529020T (pt) Plataforma de fabrico escalável para purificação de vetor viral e vetores virais assim purificados para utilização na terapia génica
ZA201309515B (en) Gene therapy vectors for adrenoleukodystrophy and adrenomyeloneuropathy
SI2753355T1 (sl) Onkolitični virus herpesa simpleksa in njegove terapevtske uporabe
GB2489900B (en) Multi-purpose wheeled conveyance
IL231604B (en) Therapeutic peptides
HUE040554T2 (hu) Kombináció antivirális terápiához
IL228031B (en) Adno vectors for gene therapy in choroideremia
EP2615109A4 (en) LOCALIZED PEGYLATED AMENDMENTS OF EXENDIN-4 ANALOGUES AND THEIR USE
PL2521562T3 (pl) Ev576 do zastosowania w leczeniu zakażeń wirusowych dróg oddechowych
HRP20181589T1 (hr) Pegilirani apelin i njegova upotreba
PL2580240T4 (pl) Przeciwciała s100a4 i ich terapeutyczne zastosowania
IL232645A0 (en) Recombinant proteins and therapeutic uses
EP2711161A4 (en) NANOPRUCTIVE FORM AND CURVED BODY
PL2897564T3 (pl) Przenośny wózek inwalidzki ze sterowaniem tylnym
GB201004143D0 (en) Promoter sequence for DNA and viral vectors
GB2497020B (en) Retractable nose saddle
IL231876A0 (en) A system for the purification of viral vectors
AU341452S (en) Alu' sling sunlounger chair
GB201020792D0 (en) Peptide agents for use in therapy
GB201014957D0 (en) Shopping handling system
GB201117876D0 (en) Peptides and their use in treatment